Alnylam Pharmaceuticals (ALNY): Strong TTR Growth and Pipeline Catalysts Ahead
Key Takeaways
- Alnylam Pharmaceuticals is positioned for robust TTR franchise growth, with 2026 guidance of $4.4-$4.7 billion in net product revenues, representing 83% growth at the midpoint from 2025.
- Pipeline advancements include four clinical readouts, three pivotal studies, three Phase 2 initiations, and three-plus new IND filings expected in 2026, expanding beyond rare diseases into cardio-metabolic areas.
- Analyst consensus leans "Moderate Buy" or "Strong Buy," with an average price target around $468, implying significant upside potential from current levels.
- Strategic partnerships, such as with Tenaya Therapeutics for cardiovascular targets (up to $1.13 billion in milestones), bolster long-term innovation.
- Macro sensitivities include biotech funding environments and regulatory approvals for RNAi therapeutics, with positive FDA trends supporting platform validation.
- Risks encompass competition in ATTR-CM from stabilizers like Pfizer's tafamidis and pricing pressures in TTR markets.
Strategic Positioning and Competitive Landscape
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
In the TTR amyloidosis market, Alnylam maintains leadership with AMVUTTRA's quarterly subcutaneous dosing and broad label for polyneuropathy and cardiomyopathy (ATTR-CM), setting it apart from oral stabilizers. The rare disease portfolio—GIVLAARI for acute hepatic porphyria and OXLUMO for primary hyperoxaluria type 1—holds monopolistic positions in underserved areas. Looking medium-term, the "Alnylam 2030" strategy aims for global TTR revenue leadership by 2030, expansion to 10 tissue types, and over 40 clinical programs, backed by partnerships with Regeneron, Roche, and Novartis. Competitors like BridgeBio in ATTR and Ionis in broader RNAi are in the mix, but Alnylam's first-mover advantage, manufacturing investments including a $250 million U.S. facility, and enzymatic ligation platform position it well for scalable growth as the industry shifts toward genetic therapies.
Major Catalysts on the Horizon
From what I see, Alnylam's path forward depends heavily on pipeline milestones and commercial execution. The Q1 2026 earnings, likely in late April, should provide updates on TTR uptake following the AMVUTTRA ATTR-CM launch anniversary, including a March 2026 webinar. Phase 3 data from CARDIO-TTRansform (vutrisiran in ATTR-CM) is expected later in 2026 and could solidify market dominance.
Regulatory milestones include ongoing reviews for vutrisiran in ATTR-CM by the EMA, PMDA, and ANVISA, plus Regeneron's planned Q1 2026 FDA submission for cemdisiran in myasthenia gravis, which would bring royalties. The Phase 3 ZENITH outcomes trial for zilebesiran (hypertension, with Roche) and KARDIA-3 completion could open up substantial markets. New Phase 2 initiations for mivelsiran (Alzheimer's, cerebral amyloid angiopathy) and ALN-6400 (bleeding disorders), along with 3+ INDs, highlight the pipeline's momentum. I also checked this using Tickeron’s AI Screener to gauge how the stock stacks up against peers in the space.
Analyst sentiment stays bullish, with 27 firms at "Moderate Buy" and an average price target of $468 (high $583, low $330). Recent moves like Jefferies' downgrade to Hold ($330, citing valuation) are balanced by Buy calls from Chardan ($425) and HC Wainwright ($510). These updates could influence views as TTR growth comes into sharper focus.
Navigating Industry and Macro Factors
The RNAi therapeutics field is growing quickly, with Alnylam at the forefront amid a broader move to genetic medicines for both rare and common diseases. Biotech funding cycles and interest rates affect R&D spending; higher rates might weigh on valuations, but Alnylam's profitability offers a buffer. Positive FDA tailwinds from six Alnylam-invented RNAi approvals validate the platform, even as pricing pressures in the U.S. and EU lead to expected mid-single-digit declines for AMVUTTRA.
Geopolitical steadiness supports launches in 60+ countries, while adoption in cardio-metabolic areas like hypertension via zilebesiran and neurology fuels expansion. Inflation impacts manufacturing costs, but the new U.S. facility helps mitigate that. Growing demand for ATTR diagnostics—where 80% remain undiagnosed—along with partnerships, adds to the company's resilience.
Insights from Tickeron’s Trend Prediction Engine
In my own research, I rely on Tickeron’s Trend Prediction Engine, an AI-powered tool that forecasts whether a stock like ALNY, ETFs, or other assets might trend bullish, bearish, or sideways over the next week or month. It uses machine learning to dissect historical price patterns, volume trends, and technical indicators, helping spot emerging trends, breakouts, or reversals. With predictions across a wide range of instruments, historical performance data, and alerts for pattern shifts, it provides a data-driven edge for decision-making. I've found it particularly useful for tracking volatile biotech names like this one.
2026 Outlook and Key Long-Term Themes
Alnylam's 2026 guidance calls for $4.9-$5.3 billion in combined net product revenues (71% growth at the midpoint), driven by TTR at $4.4-$4.7 billion and rare diseases at $500-$600 million. The "Alnylam 2030" vision targets a 25% CAGR to 2030, ~30% non-GAAP operating margins, and TTR leadership through AMVUTTRA cardiomyopathy penetration and nucresiran launches (2028 PN, 2030 CM).
Key drivers include ATTR-CM market growth from the undiagnosed pool, enzymatic manufacturing efficiencies, and margin expansion now that profitability is in place. The pipeline shifts toward cardio-metabolic (zilebesiran for hypertension), neurology (mivelsiran for AD), and bleeding disorders, aiming for 10 tissues and 40+ programs by 2030. Threats from Ionis/AstraZeneca in ATTR and regulatory challenges persist, but partnerships like Tenaya and Roche, plus R&D allocation at 30% of revenues, keep the momentum going. Consensus points to 2026 revenue of ~$5.57 billion and EPS of $9.25, which could foster positive sentiment if delivered.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ALNY in upward trend: price may jump up because it broke its lower Bollinger Band on October 01, 2026
ALNY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 26 of 33 cases where ALNY's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 79%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The 10-day moving average for ALNY crossed bullishly above the 50-day moving average on September 24, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 68%.
Following a +3.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALNY advanced for three days, in 224 of 303 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
The Aroon Indicator entered an Uptrend today. In 145 of 187 cases where ALNY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 78%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALNY as a result. In 54 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 66%.
The Moving Average Convergence Divergence Histogram (MACD) for ALNY turned negative on October 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 33 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 72%.
ALNY moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALNY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 14 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (25.253) is normal, around the industry mean (26.780). P/E Ratio (44.488) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.330) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (6.911) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. ALNY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 91 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALNY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of therapeutics based on RNA interference
Industry Biotechnology
Advertisement